🔗 Share this article

Given that America proceeds with unprecedented adjustments to its immunization recommendations, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by casting doubt on Covid vaccines in the pandemic and has concentrated on alleged fatalities following COVID-19 immunization in her recent position at the FDA.

Proposed Overhauls to Pediatric Vaccine Schedule

Public health authorities were set to reveal sweeping revisions to the childhood immunization program in December, bringing the US with the Danish immunization schedule, sources say – a significant shift that would place the US out of step with much of the global community with insufficient data for benefit. This reveal has been delayed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is listed to speak at the event. She was just designated temporary leader of the FDA’s CDER, the fifth individual to lead the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position could signify a strengthened alliance between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood shot schedules in the US to become more like Denmark's approach, a society with comprehensive healthcare and a population approximately the population of Wisconsin’s.

To date public appearances, she has continued to focus on immunizations – usually the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Expertise

The appointee has no obvious background in drug development, approval processes or leadership, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, stated Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She lacks background in drug approvals.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the research of drug development”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who led CBER have had.”

The drug center has an enormous portfolio at the FDA, Woodcock stated.

“The public just focuses on the innovative therapies, but the off-patent medication office approves thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and so forth, and every single one need to be managed,” she said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant administrative aspect to the role, which oversees more than 5,000 employees. “It’s a massive leadership role, if you do it right,” the former official concluded.

Agency Reaction and Controversial Programs

Regarding concerns about Høeg’s credentials and whether this appointment indicates more teamwork among FDA leaders on immunizations, a spokesperson stated that the “questions stem from inaccurate assumptions”.

“This background aligns with the functions of her role,” the spokesperson explained, noting the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s recently launched priority voucher program, a contentious rapid drug-approval program that apparently troubled her former heads. “How are these drugs being picked for this expedited pathway? Who takes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the FDA right now.”

Overall, he said, “the agency looks to be trending towards less stringent rules of pharmaceuticals, with the exception of shots.”

Public Track Record on Vaccines

With immunizations, Dr. Høeg has a more established, if troubling, history, some experts observe. She authored a analysis using unconfirmed volunteer-provided data to determine the frequency of heart inflammation after COVID-19 vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the new government included revising guidelines for new vaccines and discontinuing “non-essential” immunizations, she remarked post-election on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of excluding young men from obtaining COVID-19 vaccinations.

“She is an all-around dogmatist who begins with her conclusions and tailors the evidence to retrofit the science in a highly deceptive, untruthful fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg aligned with fellow skeptics, {like|